TrialCancer2016

Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.

Koji Sasaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.